Yin-Yang Balance of ACE/ACE2 Pathways: The Rational for ACE2 Pathway Inhibitor Administration in SARS-CoV-2 Patients

Loris Zamai

doi:10.20944/preprints202003.0338.v1

Version 1 : Received: 19 March 2020 / Approved: 23 March 2020 / Online: 23 March 2020 (06:29:42 CET)
Version 2 : Received: 23 March 2020 / Approved: 24 March 2020 / Online: 24 March 2020 (06:47:18 CET)
Version 3 : Received: 5 May 2020 / Approved: 6 May 2020 / Online: 6 May 2020 (04:40:25 CEST)

A peer-reviewed article of this Preprint also exists.

Zamai, L. The Yin and Yang of ACE/ACE2 Pathways: The Rationale for the Use of Renin-Angiotensin System Inhibitors in COVID-19 Patients. Cells 2020, 9, 1704. Zamai, L. The Yin and Yang of ACE/ACE2 Pathways: The Rationale for the Use of Renin-Angiotensin System Inhibitors in COVID-19 Patients. Cells 2020, 9, 1704.

Abstract

The article describes the rational for inhibition of the angiotensin-converting enzyme 2 (ACE2) pathways as specific targets in patients infected by SARS-CoV-2.

Supplementary and Associated Material

Keywords

Severe Acute Respiratory Syndrome Coronavirus-2; (soluble) ACE2; eosinophil; asthma; IL-10; IL-6; Lung fibrosis; Ang (1-7); hypoxia; infarction; hypertension

Subject

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Yin-Yang Balance of ACE/ACE2 Pathways: The Rational for ACE2 Pathway Inhibitor Administration in SARS-CoV-2 Patients

Abstract

Supplementary and Associated Material

Keywords

Subject

Comments (0)